Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$12.30 USD
+0.09 (0.74%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Arcturus Therapeutics Holdings Inc.'s return on equity, or ROE, is -27.41% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that ARCT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ARCT 12.30 +0.09(0.74%)
Will ARCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Other News for ARCT
ARCT Crosses Above Key Moving Average Level
Arcturus Therapeutics (ARCT) Maintains Sector Outperform; Price Target Raised | ARCT Stock News
Arcturus Therapeutics price target raised by $3 at Scotiabank, here's why
Arcturus Therapeutics: High Hopes, High Hurdles For Its mRNA Pipeline
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts